Budesonide + formoterol delivered via Spiromax® for the management of asthma and COPD: The potential impact on unscheduled healthcare costs of improving inhalation technique compared with Turbuhaler®. (Q47825390)
Jump to navigation
Jump to search
scientific article published on 27 June 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Budesonide + formoterol delivered via Spiromax® for the management of asthma and COPD: The potential impact on unscheduled healthcare costs of improving inhalation technique compared with Turbuhaler®. |
scientific article published on 27 June 2017 |
Statements
1 reference
Budesonide + formoterol delivered via Spiromax® for the management of asthma and COPD: The potential impact on unscheduled healthcare costs of improving inhalation technique compared with Turbuhaler®. (English)
1 reference
A Lewis
1 reference
S Torvinen
1 reference
P N R Dekhuijzen
1 reference
H Chrystyn
1 reference
A Melani
1 reference
Y Zöllner
1 reference
K Kolbe
1 reference
A T Watson
1 reference
M Blackney
1 reference
A Plich
1 reference
27 June 2017
1 reference
1 reference
129
1 reference
179-188
1 reference
Identifiers
1 reference
1 reference